- Home
- KROS vs SAGE Comparison
KROS vs SAGE Comparison
Compare KROS & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- SAGE
- Stock Information
- Founded
- KROS 2015
- SAGE 2010
- Country
- KROS United States
- SAGE United States
- Employees
- KROS N/A
- SAGE N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- KROS Health Care
- SAGE Health Care
- Exchange
- KROS Nasdaq
- SAGE Nasdaq
- Market Cap
- KROS 558.9M
- SAGE 571.7M
- IPO Year
- KROS 2020
- SAGE 2014
- Fundamental
- Price
- KROS $13.37
- SAGE $9.08
- Analyst Decision
- KROS Buy
- SAGE Hold
- Analyst Count
- KROS 13
- SAGE 18
- Target Price
- KROS $20.63
- SAGE $10.06
- AVG Volume (30 Days)
- KROS 637.6K
- SAGE 2.8M
- Earning Date
- KROS 08-06-2025
- SAGE 07-30-2025
- Dividend Yield
- KROS N/A
- SAGE N/A
- EPS Growth
- KROS N/A
- SAGE N/A
- EPS
- KROS 0.11
- SAGE N/A
- Revenue
- KROS $214,713,000.00
- SAGE $47,404,000.00
- Revenue This Year
- KROS $5,006.76
- SAGE $102.21
- Revenue Next Year
- KROS N/A
- SAGE $43.01
- P/E Ratio
- KROS $123.16
- SAGE N/A
- Revenue Growth
- KROS 91657.70
- SAGE N/A
- 52 Week Low
- KROS $9.12
- SAGE $4.62
- 52 Week High
- KROS $72.37
- SAGE $13.47
- Technical
- Relative Strength Index (RSI)
- KROS 42.27
- SAGE 71.54
- Support Level
- KROS $13.25
- SAGE $9.04
- Resistance Level
- KROS $13.99
- SAGE $9.30
- Average True Range (ATR)
- KROS 0.36
- SAGE 0.18
- MACD
- KROS -0.06
- SAGE 0.09
- Stochastic Oscillator
- KROS 20.75
- SAGE 91.35
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.